



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

August 13, 2020

Steven O'Loughlin  
Chief Financial Officer  
Actinium Pharmaceuticals, Inc.  
275 Madison Avenue, 7th Floor  
New York, NY 10016

**Re: Actinium Pharmaceuticals, Inc.**  
**Registration Statement on Form S-3**  
**Filed August 7, 2020**  
**File No. 333-242322**

Dear Mr. O'Loughlin:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Laura Crotty at (202) 551-7614 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Rick Werner